Literature DB >> 17592230

Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer.

Gaku Matsumoto1, Mariko Muta, Koji Tsuruta, Shinichiro Horiguchi, Katsuyuki Karasawa, Atsutake Okamoto.   

Abstract

BACKGROUND/AIM: Local treatment often fails in patients with resectable pancreatic cancer due to the postoperative development of distant metastases, especially liver metastases. We determined the prognostic factors for postoperative liver metastases in pancreatic cancer patients following surgical resection with combined radiotherapy.
METHODS: Sixty-four patients with nonmetastatic, resectable pancreatic cancer were entered into this study. All of these patients had pancreatic resection surgery combined with radiotherapy. The development of postoperative liver metastases was carefully followed, and the survival ratio was evaluated using the Kaplan-Meier method. The prognostic importance of clinicopathological factors and molecular characteristics was analyzed by the Cox proportional hazards model. The correlation study was performed using Fisher's exact test.
RESULTS: Tumor size, curability, and histological type of differentiation were statistically significant independent prognostic factors. On multivariate analysis, curability and histological type of differentiation were statistically significant. Only tumor size (> or = 3 cm) was significantly correlated with postoperative liver metastases, as well as cyclooxygenase-2 expression.
CONCLUSIONS: There were three significant prognostic factors in patients with resectable pancreatic cancer who had local therapy. Patients who have a large tumor require particularly careful follow-up for postoperative liver metastases. (c) 2007 S. Karger AG, Basel and IAP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592230     DOI: 10.1159/000104241

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  6 in total

1.  Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Marek Olakowski; Pawel Lampe; Beata Smolarz; Hanna Romanowicz-Makowska; Ewa Malecka-Panas
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

2.  Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.

Authors:  Marketa Hermanova; Petr Karasek; Jiri Tomasek; Jiri Lenz; Jiri Jarkovsky; Petr Dite
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

3.  Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.

Authors:  Jinbo Shi; Xiawei Li; Yulian Wu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

4.  Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.

Authors:  Burcu Saka; Serdar Balci; Olca Basturk; Pelin Bagci; Lauren M Postlewait; Shishir Maithel; Jessica Knight; Bassel El-Rayes; David Kooby; Juan Sarmiento; Takashi Muraki; Irma Oliva; Sudeshna Bandyopadhyay; Gizem Akkas; Michael Goodman; Michelle D Reid; Alyssa Krasinskas; Rhonda Everett; Volkan Adsay
Journal:  Ann Surg Oncol       Date:  2016-01-29       Impact factor: 5.344

5.  How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery-Superior Mesenteric Artery Lymph Node Regions.

Authors:  Rei Umezawa; Yoshinori Ito; Akihisa Wakita; Satoshi Nakamura; Hiroyuki Okamoto; Kana Takahashi; Koji Inaba; Naoya Murakami; Hiroshi Igaki; Keiichi Jingu; Jun Itami
Journal:  Adv Radiat Oncol       Date:  2019-09-13

Review 6.  Targeting Lipid Peroxidation for Cancer Treatment.

Authors:  Sofia M Clemente; Oscar H Martínez-Costa; Maria Monsalve; Alejandro K Samhan-Arias
Journal:  Molecules       Date:  2020-11-05       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.